Is Cadila Healthcare Ltd a good quality company?

MoneyWorks4Me analysed the past 10-year performance of Cadila Healthcare Ltd and arrived at the following conclusion.

Is the current market price of Cadila Healthcare Ltd a good price to buy it?

The 5-year analysis of Cadila Healthcare Ltd's performance infers.

What is Cadila Healthcare Ltd share price return in the past 10 years?

We analysed the performance of Cadila Healthcare Ltd share prices over the last 10 years. Here is what we found out:

What is a Financial Track Record? How to read this chart in order to understand the data present here?

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance

Difference between Standalone Basis and Consolidated basis? Which method is preferred for Cadila Healthcare Ltd

Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.

What is CAGR? What does CAGR table indicate for Cadila Healthcare Ltd?

Compounded average growth rate (CAGR) measures the average annual growth rate compounded year-on-year over a period of time.

Cadila Healthcare submits press release

Cadila Healthcare Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 532321 | NSE: CADILAHC

24 Jul 2019

Evaluate

Cadila Healthcare has informed about submission of a copy of press release dated July 24, 2019 titled ‘Zydus has launched Ramelteon Tablets in the US upon receiving final approval from the USFDA’. The contents of the press release give full details.

The above information is a part of company’s filings submitted to BSE.

Related Cadila Healthcare Ltd. Links:

Analysis

Reports

News

Stock Price

Sector News